Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

37.15 -0.07 (-0.20%)
Streaming Delayed Price Updated: 12:31 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
From QIAGEN N.V.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
QIAGEN N.V. (NYSE:QGEN) Q1 Earnings Miss Estimates, Guidance Cut Sinks Stock ↗
Via Chartmill
Topics Earnings
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
From Pomerantz LLP
Via GlobeNewswire
News headline image
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V. on Behalf of Qiagen Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
QGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
From QIAGEN N.V.
Via Business Wire
News headline image
Water Utility Up Just 8% in a Year Faces $28 Million Position Cut ↗
H2O America provides regulated water and wastewater services to over 1.6 million people, focusing on stable, tariff-driven revenue streams. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Qiagen (QGEN) Q1 2026 Earnings Transcript ↗
Qiagen (QGEN) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
From QIAGEN N.V.
Via Business Wire
News headline image
QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
QIAGEN Reports Full Results for Q1 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
From QIAGEN N.V.
Via Business Wire
News headline image
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Mark Stevenson to Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.